Review



lenticrisprv2 vector expressing streptococcus pyogenes cas9 spcas9  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Addgene inc lenticrisprv2 vector expressing streptococcus pyogenes cas9 spcas9
    Lenticrisprv2 Vector Expressing Streptococcus Pyogenes Cas9 Spcas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 6129 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/pmc12874916-148-17-24
    Average 96 stars, based on 6129 article reviews
    lenticrisprv2 vector expressing streptococcus pyogenes cas9 spcas9 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer
    Article Snippet: .. These include pX330U6-Chimeric_BB-CBh-hSpCas9 (Addgene #42230), LentiCRISPR v2 expression vector (Addgene #52961), LentiCas9-Blast (Addgene #52962), and LRG (Addgene #65656). ..

    Article Title: APC and P53 mutations synergize to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer
    Article Snippet: .. The pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene#42230), LentiCRISPR v2 expression vector (Addgene# 52961), LentiCas9-Blast (Addgene# 52962) and LRG (Addgene# 65656) which expressed sgRNA and/or Cas9 nuclease were used to generate gene-specific sgRNA vectors. ..

    Plasmid Preparation:

    Article Title: APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer
    Article Snippet: .. These include pX330U6-Chimeric_BB-CBh-hSpCas9 (Addgene #42230), LentiCRISPR v2 expression vector (Addgene #52961), LentiCas9-Blast (Addgene #52962), and LRG (Addgene #65656). ..

    Article Title: APC and P53 mutations synergize to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer
    Article Snippet: .. The pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene#42230), LentiCRISPR v2 expression vector (Addgene# 52961), LentiCas9-Blast (Addgene# 52962) and LRG (Addgene# 65656) which expressed sgRNA and/or Cas9 nuclease were used to generate gene-specific sgRNA vectors. ..



    Similar Products

    96
    Addgene inc lenticrisprv2 vector expressing streptococcus pyogenes cas9 spcas9
    Lenticrisprv2 Vector Expressing Streptococcus Pyogenes Cas9 Spcas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/pmc12874916-148-17-24
    Average 96 stars, based on 1 article reviews
    lenticrisprv2 vector expressing streptococcus pyogenes cas9 spcas9 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Addgene inc lentiviral grna expression vector
    A. CRISPR screening timeline. Cells were transduced with the Brunello genome-wide CRISPR screening library at low MOI, selected with puromycin, and passaged for eight days. They were then treated with 100 nM dexamethasone or 0.1% ethanol as a vehicle control for four hours, stained with an anti-GILZ antibody, and sorted into high and low expression bins containing the top and bottom 10% GILZ-expressing cells.. gDNA was collected from cells, <t>gRNA</t> sequences were amplified, and enrichment in high and low bins vs. the bulk population was determined (n = 5 replicates per drug condition). B,C. Differential gRNA enrichment in the high and low GILZ expression bins in B. the vehicle control condition and C. the 100 nM dexamethasone treatment condition. Log 2 fold changes are an average of high bin vs. bulk unsorted and low bin vs. bulk unsorted. Negative sign indicates a gRNA was depleted from the high bin and enriched in the low bin. (n = 5 replicates per drug condition) D,E. Validation of top gRNAs from the screen using D. qPCR or E. flow cytometry to determine the impact of knocking out the target gene on glucocorticoid-induced GILZ expression (n = 3 independent transductions). * p < 0.05, ** p < 0.01, *** p <0.001, one-tailed student’s t-test. Samples transduced with non-targeting control gRNAs are shown in gray, positive control gRNAs targeting NR3C1 and TSC22D3 are in blue, and gRNAs targeting SMARCA2 and BPTF in red. F,G. Validation of top hits from the screen using siRNAs to knock down the genes of interest and assess their impact on glucocorticoid-induced GILZ expression using F. qPCR (n = 2 to n = 3 independent transfections) or G. flow cytometry (n = 4 independent transfections) * p < 0.05, ** p < 0.01, *** p <0.001, one-tailed student’s t-test
    Lentiviral Grna Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/bio_rxiv__2025__11__13__688306-305-21-27
    Average 96 stars, based on 1 article reviews
    lentiviral grna expression vector - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Addgene inc lentiviral dual grna cas9 expression vector lenticrisprv2 blast
    A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ <t>Cas9</t> -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.
    Lentiviral Dual Grna Cas9 Expression Vector Lenticrisprv2 Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2-Blast+(Plasmid+%2383480)/pmc12501213-192-6-13
    Average 96 stars, based on 1 article reviews
    lentiviral dual grna cas9 expression vector lenticrisprv2 blast - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Addgene inc cas9 sgrna expression vectors
    A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ <t>Cas9</t> -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.
    Cas9 Sgrna Expression Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/us12371709-430-43-47
    Average 96 stars, based on 1 article reviews
    cas9 sgrna expression vectors - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Addgene inc lentiviral expression vector for cas9
    A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ <t>Cas9</t> -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.
    Lentiviral Expression Vector For Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/pm40389477-281-27-34
    Average 96 stars, based on 1 article reviews
    lentiviral expression vector for cas9 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Addgene inc lenticrispr v2 crisprko sgrna expression vector
    A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ <t>Cas9</t> -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.
    Lenticrispr V2 Crisprko Sgrna Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/10__1158_slash_2159___8290__cd___24___1378-147-13-19
    Average 96 stars, based on 1 article reviews
    lenticrispr v2 crisprko sgrna expression vector - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Addgene inc bicistronic expression vector
    A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ <t>Cas9</t> -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.
    Bicistronic Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+vector/lentiCRISPR+v2+(Plasmid+%2352961)/pmc11844325-307-11-21
    Average 96 stars, based on 1 article reviews
    bicistronic expression vector - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    A. CRISPR screening timeline. Cells were transduced with the Brunello genome-wide CRISPR screening library at low MOI, selected with puromycin, and passaged for eight days. They were then treated with 100 nM dexamethasone or 0.1% ethanol as a vehicle control for four hours, stained with an anti-GILZ antibody, and sorted into high and low expression bins containing the top and bottom 10% GILZ-expressing cells.. gDNA was collected from cells, gRNA sequences were amplified, and enrichment in high and low bins vs. the bulk population was determined (n = 5 replicates per drug condition). B,C. Differential gRNA enrichment in the high and low GILZ expression bins in B. the vehicle control condition and C. the 100 nM dexamethasone treatment condition. Log 2 fold changes are an average of high bin vs. bulk unsorted and low bin vs. bulk unsorted. Negative sign indicates a gRNA was depleted from the high bin and enriched in the low bin. (n = 5 replicates per drug condition) D,E. Validation of top gRNAs from the screen using D. qPCR or E. flow cytometry to determine the impact of knocking out the target gene on glucocorticoid-induced GILZ expression (n = 3 independent transductions). * p < 0.05, ** p < 0.01, *** p <0.001, one-tailed student’s t-test. Samples transduced with non-targeting control gRNAs are shown in gray, positive control gRNAs targeting NR3C1 and TSC22D3 are in blue, and gRNAs targeting SMARCA2 and BPTF in red. F,G. Validation of top hits from the screen using siRNAs to knock down the genes of interest and assess their impact on glucocorticoid-induced GILZ expression using F. qPCR (n = 2 to n = 3 independent transfections) or G. flow cytometry (n = 4 independent transfections) * p < 0.05, ** p < 0.01, *** p <0.001, one-tailed student’s t-test

    Journal: bioRxiv

    Article Title: SMARCA2 is an essential and potent cofactor for a specific subset of the glucocorticoid response in A549 cells

    doi: 10.1101/2025.11.13.688306

    Figure Lengend Snippet: A. CRISPR screening timeline. Cells were transduced with the Brunello genome-wide CRISPR screening library at low MOI, selected with puromycin, and passaged for eight days. They were then treated with 100 nM dexamethasone or 0.1% ethanol as a vehicle control for four hours, stained with an anti-GILZ antibody, and sorted into high and low expression bins containing the top and bottom 10% GILZ-expressing cells.. gDNA was collected from cells, gRNA sequences were amplified, and enrichment in high and low bins vs. the bulk population was determined (n = 5 replicates per drug condition). B,C. Differential gRNA enrichment in the high and low GILZ expression bins in B. the vehicle control condition and C. the 100 nM dexamethasone treatment condition. Log 2 fold changes are an average of high bin vs. bulk unsorted and low bin vs. bulk unsorted. Negative sign indicates a gRNA was depleted from the high bin and enriched in the low bin. (n = 5 replicates per drug condition) D,E. Validation of top gRNAs from the screen using D. qPCR or E. flow cytometry to determine the impact of knocking out the target gene on glucocorticoid-induced GILZ expression (n = 3 independent transductions). * p < 0.05, ** p < 0.01, *** p <0.001, one-tailed student’s t-test. Samples transduced with non-targeting control gRNAs are shown in gray, positive control gRNAs targeting NR3C1 and TSC22D3 are in blue, and gRNAs targeting SMARCA2 and BPTF in red. F,G. Validation of top hits from the screen using siRNAs to knock down the genes of interest and assess their impact on glucocorticoid-induced GILZ expression using F. qPCR (n = 2 to n = 3 independent transfections) or G. flow cytometry (n = 4 independent transfections) * p < 0.05, ** p < 0.01, *** p <0.001, one-tailed student’s t-test

    Article Snippet: The protospacers from the top enriched gRNAs found in the screen were ordered as oligonucleotides from IDT and cloned into a lentiviral gRNA expression vector (lentiCRISPR v2, Addgene Plasmid #52961).

    Techniques: CRISPR, Transduction, Genome Wide, Control, Staining, Expressing, Amplification, Biomarker Discovery, Flow Cytometry, One-tailed Test, Positive Control, Knockdown, Transfection

    A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ Cas9 -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.

    Journal: Cell Death & Disease

    Article Title: MEK5/ERK5 inhibition sensitizes NRAS -mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression

    doi: 10.1038/s41419-025-08036-7

    Figure Lengend Snippet: A : Representative immunoblots of n = 3 experiments done using total lysates from BLM wild-type (Wt), BLM empty vector (EV)-infected, or two different CRISPR/ Cas9 -mediated MEK5 k.o. single cell clones (SCC) of BLM treated with diluent (ctrl) or 25 nM Tram for 14 days, showing expression of selected cell cycle proteins. ERK5 phosphorylation and DUSP4 suppression confirm Tram functionality. Successful MEK5 gene disruption was analysed by MEK5 immunoblot and functionally evaluated by immunoblotting for ERK5, which confirmed absent ERK5 autophosphorylation. Tubulin served as loading control. B : Representative cell cycle profiles of n = 2 experiments, as determined by flow cytometric analysis of the indicated PI-stained conditions with percentages of S-phase cells indicated. C : Cell doubling time analysis representative of n = 2 experiments with running times of 2–5 weeks performed with Wt BLM or the indicated MEK5 k.o. BLM SCCs cultured in absence or presence of Tram. The shown experiment run over a period of five weeks.

    Article Snippet: BLM, lentiCRISPR_zeo, a derivative of the lentiviral dual gRNA/ Cas9 expression vector lentiCRISPRv2-Blast (Addgene_83480) replacing the blasticidin R gene by a zeocin R gene was used.

    Techniques: Western Blot, Plasmid Preparation, Infection, CRISPR, Clone Assay, Expressing, Phospho-proteomics, Disruption, Control, Staining, Cell Culture